Vyome Holdings (HIND) Company Report

Vyome Holdings reported its first full quarter as a publicly listed company, ending Q3 2025 with approximately $5.7 million in cash, cash equivalents, and short-term investments, providing a runway through 2026.
The company completed a streamlined NASDAQ listing and achieved a lower cash burn than anticipated, demonstrating operational efficiency.
Encouraging interim phase two results for VT1953 in treating malignant fungating wounds showed significant reduction in malodor and pain, with full phase two data expected in December 2025.
Strong preclinical efficacy was reported for VT1908 eye drops in uveitis models, with FDA interactions planned for the first half of 2026.
Vyome is also exploring an AI-focused healthcare initiative through the acquisition of Oculos and MIT Spinout, and has strengthened its leadership team with key hires.

Nov 20, 2025, 3:00 PM

Vyome Holdings Reports Q3 2025 Results, Highlights Pipeline Progress and Financial Runway

HIND

Earnings

Guidance Update

New Projects/Investments

Vyome Holdings, in its first full quarter as a public company, reported $5.7 million in cash, cash equivalents, and short-term investments as of September 30, 2025, projecting a runway through 2026. The company recorded a net loss of $9.2 million for Q3 2025.
The lead program, VT1953, delivered encouraging interim Phase 2 results for malignant fungating wounds, showing significant reductions in malodor and pain, with full Phase 2 data anticipated in December 2025.
VT1908, the second program, demonstrated strong preclinical efficacy in uveitis models, with FDA interactions planned for the first half of 2026.
The company achieved a lower cash burn than anticipated due to disciplined spending and is exploring an AI-focused healthcare initiative via the acquisition of Oculos.